144 related articles for article (PubMed ID: 24984178)
1. The effect of a single nucleotide polymorphism of the CYP4F2 gene on blood pressure and 20-hydroxyeicosatetraenoic acid excretion after weight loss.
Ward NC; Croft KD; Puddey IB; Phillips M; van Bockxmeer F; Beilin LJ; Barden AE
J Hypertens; 2014 Jul; 32(7):1495-502; discussion 1502. PubMed ID: 24984178
[TBL] [Abstract][Full Text] [Related]
2. A single nucleotide polymorphism in the CYP4F2 but not CYP4A11 gene is associated with increased 20-HETE excretion and blood pressure.
Ward NC; Tsai IJ; Barden A; van Bockxmeer FM; Puddey IB; Hodgson JM; Croft KD
Hypertension; 2008 May; 51(5):1393-8. PubMed ID: 18391101
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of cytochrome P450 4F2 in mice increases 20-hydroxyeicosatetraenoic acid production and arterial blood pressure.
Liu X; Zhao Y; Wang L; Yang X; Zheng Z; Zhang Y; Chen F; Liu H
Kidney Int; 2009 Jun; 75(12):1288-1296. PubMed ID: 19279555
[TBL] [Abstract][Full Text] [Related]
4. Interaction Between CYP4F2 rs2108622 and CPY4A11 rs9333025 Variants Is Significantly Correlated with Susceptibility to Ischemic Stroke and 20-Hydroxyeicosatetraenoic Acid Level.
Liao D; Yi X; Zhang B; Zhou Q; Lin J
Genet Test Mol Biomarkers; 2016 May; 20(5):223-8. PubMed ID: 26959478
[TBL] [Abstract][Full Text] [Related]
5. The T8590C polymorphism of CYP4A11 and 20-hydroxyeicosatetraenoic acid in essential hypertension.
Laffer CL; Gainer JV; Waterman MR; Capdevila JH; Laniado-Schwartzman M; Nasjletti A; Brown NJ; Elijovich F
Hypertension; 2008 Mar; 51(3):767-72. PubMed ID: 18227405
[TBL] [Abstract][Full Text] [Related]
6. Intakes of omega-3 polyunsaturated fatty acids and blood pressure change over time: Possible interaction with genes involved in 20-HETE and EETs metabolism.
Tagetti A; Ericson U; Montagnana M; Danese E; Almgren P; Nilsson P; Engström G; Hedblad B; Minuz P; Orho-Melander M; Fava C; Melander O
Prostaglandins Other Lipid Mediat; 2015 Jul; 120():126-33. PubMed ID: 25986600
[TBL] [Abstract][Full Text] [Related]
7. Metabolism of arachidonic acid to 20-hydroxy-5,8,11, 14-eicosatetraenoic acid by P450 enzymes in human liver: involvement of CYP4F2 and CYP4A11.
Powell PK; Wolf I; Jin R; Lasker JM
J Pharmacol Exp Ther; 1998 Jun; 285(3):1327-36. PubMed ID: 9618440
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of CMV and KAP promoters for driving the expression of human CYP4F2 in transgenic mice.
Lai G; Liu X; Wu J; Liu H; Zhao Y
Int J Mol Med; 2012 Jan; 29(1):107-12. PubMed ID: 21887457
[TBL] [Abstract][Full Text] [Related]
9. The V433M variant of the CYP4F2 is associated with ischemic stroke in male Swedes beyond its effect on blood pressure.
Fava C; Montagnana M; Almgren P; Rosberg L; Lippi G; Hedblad B; Engström G; Berglund G; Minuz P; Melander O
Hypertension; 2008 Aug; 52(2):373-80. PubMed ID: 18574070
[TBL] [Abstract][Full Text] [Related]
10. Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension.
Gainer JV; Bellamine A; Dawson EP; Womble KE; Grant SW; Wang Y; Cupples LA; Guo CY; Demissie S; O'Donnell CJ; Brown NJ; Waterman MR; Capdevila JH
Circulation; 2005 Jan; 111(1):63-9. PubMed ID: 15611369
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel CYP4F2 genetic variants exhibiting decreased catalytic activity in the conversion of arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE).
Kim WY; Lee SJ; Min J; Oh KS; Kim DH; Kim HS; Shin JG
Prostaglandins Leukot Essent Fatty Acids; 2018 Apr; 131():6-13. PubMed ID: 29628049
[TBL] [Abstract][Full Text] [Related]
12. 20-HETE and F2-isoprostanes in the metabolic syndrome: the effect of weight reduction.
Tsai IJ; Croft KD; Mori TA; Falck JR; Beilin LJ; Puddey IB; Barden AE
Free Radic Biol Med; 2009 Jan; 46(2):263-70. PubMed ID: 19013235
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for post-transplant diabetes mellitus in renal transplant: Role of genetic variability in the CYP450-mediated arachidonic acid metabolism.
Gervasini G; Luna E; García-Cerrada M; García-Pino G; Cubero JJ
Mol Cell Endocrinol; 2016 Jan; 419():158-64. PubMed ID: 26483195
[TBL] [Abstract][Full Text] [Related]
14. Vascular characterization of mice with endothelial expression of cytochrome P450 4F2.
Cheng J; Edin ML; Hoopes SL; Li H; Bradbury JA; Graves JP; DeGraff LM; Lih FB; Garcia V; Shaik JS; Tomer KB; Flake GP; Falck JR; Lee CR; Poloyac SM; Schwartzman ML; Zeldin DC
FASEB J; 2014 Jul; 28(7):2915-31. PubMed ID: 24668751
[TBL] [Abstract][Full Text] [Related]
15. Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of Cyp4F2 and Cyp4A11.
Lasker JM; Chen WB; Wolf I; Bloswick BP; Wilson PD; Powell PK
J Biol Chem; 2000 Feb; 275(6):4118-26. PubMed ID: 10660572
[TBL] [Abstract][Full Text] [Related]
16. Functional polymorphism in human CYP4F2 decreases 20-HETE production.
Stec DE; Roman RJ; Flasch A; Rieder MJ
Physiol Genomics; 2007 Jun; 30(1):74-81. PubMed ID: 17341693
[TBL] [Abstract][Full Text] [Related]
17. Peripheral and central augmentation indexes in relation to the CYP4F2 polymorphisms in Chinese.
Hu BC; Li Y; Li FH; Zhang Y; Sheng CS; Fan HQ; Wang JG
J Hypertens; 2011 Mar; 29(3):501-8. PubMed ID: 21150635
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of 20-hydroxyeicosatetraenoic acid synthesis using specific plant lignans: in vitro and human studies.
Wu JH; Hodgson JM; Clarke MW; Indrawan AP; Barden AE; Puddey IB; Croft KD
Hypertension; 2009 Nov; 54(5):1151-8. PubMed ID: 19786646
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Novel Pyrazolylpyridine Derivatives for 20-Hydroxyeicosatetraenoic Acid Synthase Inhibitors with Selective CYP4A11/4F2 Inhibition.
Kawamura M; Kobashi Y; Tanaka H; Bohno-Mikami A; Hamada M; Ito Y; Hirata T; Ohara H; Kojima N; Koretsune H; Gunji E; Fukunaga T; Inatani S; Hasegawa Y; Suzuki A; Takahashi T; Kakinuma H
J Med Chem; 2022 Nov; 65(21):14599-14613. PubMed ID: 36318660
[TBL] [Abstract][Full Text] [Related]
20. The frequency of cytochrome 4F2 rs2108622 genetic variant and its effects on the lipid profile and complications of type II diabetes among a sample of patients in Jordan: A pilot study.
Jarrar Y; Alkhalili M; Alhawari H; Abaalkhail SJ; Alkhalili S; Alhawari H; Momani M; Obeidat AN; Fram RK
Prostaglandins Other Lipid Mediat; 2023 Apr; 165():106715. PubMed ID: 36758722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
